MedTrace Logo

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

NCT00036426 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink their tumor.

Conditions

  • Lymphoma, Low-Grade

Interventions

BIOLOGICAL

FavId (Id-KLH) active immunotherapy

Sponsors & Collaborators

  • Favrille

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036426 on ClinicalTrials.gov